10-K/A: Plus Therapeutics Files Amendment to 10-K to Include Omitted Information

Plus Therapeutics files an amendment to its 2024 Annual Report on Form 10-K to include information previously omitted from Part III, Items 10 through 14, and updates the exhibit list and share outstanding information.

Summary

• Plus Therapeutics has filed Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
• The amendment includes information required by Part III, Items 10 through 14 of the 2024 Form 10-K, which were initially omitted.
• New certifications by the company's principal executive officer and principal financial officer under Section 302 of the Sarbanes-Oxley Act of 2002 are filed as exhibits.
• The cover page has been updated to reflect 16,999,626 shares of common stock outstanding as of April 18, 2025.
• The amendment also removes the statement about incorporating information by reference from the definitive proxy statement.
• The original filing continues to speak as of its original date, and disclosures have not been updated to reflect subsequent events.
• The document details information about the company's directors, executive officers, corporate governance, executive compensation, security ownership, related party transactions, and principal accounting fees and services.

Sentiment

Score: 6

Explanation: The document is primarily factual and descriptive, providing information about corporate governance, executive compensation, and related matters. The sentiment is neutral, with no strong positive or negative indicators.

Positives

• The company has a Code of Business Conduct and Ethics applicable to all directors, officers, and employees.
• The Board has determined that all members of the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee are independent directors.
• The company has adopted an insider trading policy to promote compliance with applicable laws and regulations.
• The company's compensation committee retained Anderson Pay Advisors in January 2023 and January 2024, to perform an independent compensation review and to provide compensation research, analysis and recommendations relating to executive compensation.

Negatives

• The company's common stock has been subject to multiple reverse stock splits in recent years: a 1-for-15 split in May 2016, a 1-for-10 split in May 2018, a 1-for-50 split in August 2019 and a 1-for-15 reverse stock split in May 2023.
• Greg Petersen resigned from the Board and his committee positions on April 18, 2025.
• Norman LaFrance, M.D., stepped down from his position as the Company's Chief Medical Officer on June 11, 2024.

Risks

• The company's success depends on retaining key personnel, including executive officers and directors.
• The company faces risks related to compliance with applicable insider trading laws and regulations.
• The company's financial performance is subject to various factors, including market conditions and competition.
• The company's future performance is dependent on the success of its clinical, financial and operational goals.

Future Outlook

The compensation level of the company's non-employee directors is expected to remain the same in 2025.

Industry Context

The document provides insights into the corporate governance and executive compensation practices of a publicly traded biotechnology company, which is relevant for understanding industry standards and benchmarks.

Comparison to Industry Standards

• Director compensation is benchmarked against comparable companies to ensure competitiveness.
• Executive compensation is reviewed in relation to compensation paid by other public companies and data from the Radford Global Life Sciences Survey.
• The company's corporate governance practices are aligned with Nasdaq listing rules and SEC regulations.
• The company's compensation committee retained Anderson Pay Advisors in January 2023 and January 2024, to perform an independent compensation review and to provide compensation research, analysis and recommendations relating to executive compensation.

Management Changes

Corporate Governance

Related Party Transactions

• In May 2024, the company entered into a purchase agreement whereby it issued and sold in a private placement (the May 2024 PIPE Financing) shares of common stock and warrants for aggregate gross proceeds of approximately $19.25 million.
• Among the purchasers were certain of our directors and officers.

Stakeholder Impact

• The information provided in the amendment is relevant to shareholders for making informed investment decisions.
• The company's corporate governance practices and executive compensation programs impact employees and other stakeholders.
• The company's financial performance and strategic goals affect its relationships with suppliers, customers, and creditors.

Next Steps

• The company will continue to monitor and review its corporate governance practices and executive compensation programs.
• The company will hold annual self-evaluations of the Board and Board committees.
• The company will oversee succession planning and processes for its Chief Executive Officer.

Key Dates

Keywords

corporate governance, executive compensation, directors, financial statements, Form 10-K, Plus Therapeutics, amendment, officers